Abstract 79P
Background
The combination of chemotherapy and ICIs based on CPS cut-off >=5 is considered standard in advanced GCs. There is emerging data on the use of low dose (LD) ICIs in multiple cancers.
Methods
Data of patients with MSS advanced GCs receiving chemotherapy combined with ICIs between August 2021 and February 2024 was collated from eight institutions in India. The co-primary endpoints of the study were to identify the predictive value of a CPS cutoff >=5 [using Ventana SP263 or the Dako PD-L1 22C3 assay) being statistically significant in predicting for improved median OS and to compare median OS between patients receiving standard dose ICIs (SD-ICI) and LD-ICIs in patients with CPS >=5. Median OS was computed by Kaplan-Meier method.
Results
A total of 262 patients were available for analysis during the study period. The majority of patients received ICIs during second line therapy or beyond as opposed to first line therapy (148, 56% vs 114, 44%), with 201 patients (77%) receiving nivolumab (SD – 94, LD – 107) and 61 patients (23%) receiving pembrolizumab (SD-60; LD-1). With a median follow up of 12.5 months [95% Confidence interval (CI): 9.4-15.6], the median OS of the entire cohort was 14.4 months (95% CI: 10.3-18.6). The CPS cutoff >=5 (n=163) did not achieve statistical significance in predicting for improved OS compared to CPS<5 (n=99), during 1st line therapy (p=0.46) and or during later lines therapy (p=0.062). In patients with CPS>=5 (n=163), there was no significant differences in median OS in patients receiving LD-ICI (n=78) as compared to SD-ICI (n=85) (14.1 months vs. 16.1 months; p=0.95). No differences in OS were seen between the LD-ICI and SD-ICI cohorts, whether used initially or during later lines of therapy (p=0.988).
Conclusions
The use of a CPS cutoff >=5 for predicting outcomes in MSS advanced gastric adenocarcinomas probably needs to be standardized with respect to various platforms and re-visited for relevance in real world practice. Low dose immune checkpoint inhibitors can be evaluated in combination with chemotherapy in patients where standard dosing is not feasible due to logistics, pending evidence from prospective trials.
Legal entity responsible for the study
Tata Memorial Centre, Mumbai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract